Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - insulin therapy in all type of patients - intensive therapy in all type of patients - prevention in all type of patients - prevention in people with impaired glucose tolerance - glucose lowering for cardiovascular prevention in all type of patients

Eliaschewitz glargine481 (231/250)
Fonseca glargine100 (52/48)
Massi glargine578 (293/285)
Pan glargine443 (220/223)
Philis-Tsimikas glargine498 (334/164)
Rosenstock glargine518 (259/259)
Wang glargine24 (16/8)
Yki-Yarvinen glargine422 (214/208)
Yki-Yarvinen glargine110 (61/49)
Yokoyamaglargine62 (31/31)
Riddle POC 4002 Glargine, 2003glargineNPHNA
HOE 901/3002, 2000glargineNPHNA
Riddle glargineNPH + SU756 (367/389)
OPAL, 2008glulisine + glargineglulisine + glargineNA
ORIGINE, 2012insulin glarginecontrol12537 (6264/6273) NCT00069784
GRACE - ORIGIN (glargine), 2012insulin glargineplacebo1184
Levin, 2011insulin glargine plus insulin glulisinepremixed insulin analoguesNA
Owens, 2011insulin glulisine + glargineglargine once daily106 (49/57)
Herman, 2005lispro +glarginecontinuous infusionNA
Fritche morning insulin glarginebedtime insulin glargine695 (463/232)

Impaired fasting glucose - prevention in all type of patients

GRACE - ORIGIN (glargine), 2012insulin glargineplacebo1184



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons